Department of Pathophysiology, Capital Medical University, Beijing, China.
PLoS One. 2011;6(9):e24868. doi: 10.1371/journal.pone.0024868. Epub 2011 Sep 13.
Coronary artery disease and ischemic heart disease are leading causes of heart failure and death. Reduced blood flow to heart tissue leads to decreased heart function and symptoms of heart failure. Therapies to improve heart function in chronic coronary artery disease are important to identify. HMG-CoA reductase inhibitors (statins) are an important therapy for prevention of coronary artery disease, but also have non-cholesterol lowering effects. Our prior work showed that pravastatin improves contractile function in the chronically ischemic heart in pigs. Endothelial progenitor cells are a potential source of new blood vessels in ischemic tissues. While statins are known to increase the number of early outgrowth endothelial progenitor cells, their effects on late outgrowth endothelial progenitor cells (LOEPCs) and capillary density in ischemic heart tissue are not known. We hypothesized that statins exert positive effects on the mobilization and growth of late outgrowth EPCs, and capillary density in ischemic heart tissue.
METHODOLOGY/PRINCIPAL FINDINGS: We determined the effects of statins on the mobilization and growth of late outgrowth endothelial progenitor cells from pigs. We also determined the density of capillaries in myocardial tissue in pigs with chronic myocardial ischemia with or without treatment with pravastatin. Pravastatin therapy resulted in greater than two-fold increase in CD31+ LOEPCs versus untreated animals. Addition of pravastatin or simvastatin to blood mononuclear cells increased the number of LOEPCs greater than three fold in culture. Finally, in animals with chronic myocardial ischemia, pravastatin increased capillary density 46%.
Statins promote the derivation, mobilization, and clonal growth of LOEPCs. Pravastatin therapy in vivo increases myocardial capillary density in chronically ischemic myocardium, providing an in vivo correlate for the effects of statins on LOEPC growth in vitro. Our findings provide evidence that statin therapy can increase the density of capillaries in the chronically ischemic heart.
冠状动脉疾病和缺血性心脏病是心力衰竭和死亡的主要原因。流向心脏组织的血液减少会导致心脏功能下降和心力衰竭症状。寻找改善慢性冠状动脉疾病患者心脏功能的疗法非常重要。羟甲基戊二酰辅酶 A 还原酶抑制剂(他汀类药物)是预防冠状动脉疾病的重要疗法,但也具有降低胆固醇以外的作用。我们之前的工作表明,普伐他汀可改善猪慢性缺血心脏的收缩功能。内皮祖细胞是缺血组织中新生血管的潜在来源。虽然他汀类药物已知可以增加早期出芽内皮祖细胞的数量,但它们对缺血心脏组织中晚期出芽内皮祖细胞(LOEPC)和毛细血管密度的影响尚不清楚。我们假设他汀类药物对 LOEPC 的动员和生长以及缺血心脏组织中的毛细血管密度产生积极影响。
方法/主要发现:我们确定了他汀类药物对猪晚期出芽内皮祖细胞的动员和生长的影响。我们还确定了慢性心肌缺血猪在未经普伐他汀治疗或治疗后的心肌组织中毛细血管密度。与未治疗的动物相比,普伐他汀治疗导致 CD31+LOEPC 增加了两倍以上。向血液单核细胞中添加普伐他汀或辛伐他汀可使 LOEPC 的数量在培养中增加三倍以上。最后,在慢性心肌缺血的动物中,普伐他汀使毛细血管密度增加了 46%。
他汀类药物促进 LOEPC 的衍生、动员和克隆生长。普伐他汀治疗可增加慢性缺血心肌中的毛细血管密度,为他汀类药物在体外对 LOEPC 生长的影响提供了体内相关性。我们的研究结果表明,他汀类药物治疗可增加慢性缺血心脏中的毛细血管密度。